Cocrystal Pharma: Funding, Investors & Team (Sep 2026)
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in Phase 2a studies for the treatment of hepatitis C as part of a cocktail for ultra-short therapy. Cocrystal recently entered into an exclusive worldwide license and collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, the Company’s molecule for the treatment of influenza A, is currently being evaluated in preclinical IND-enabling studies. In addition, the Company has a pipeline of promising early preclinical programs and continues to identify and develop non-nucleoside polymerase inhibitors for norovirus gastroenteritis using the Company’s proprietary structure-based drug design technology platform.
Cocrystal Pharma has raised $4.0M across 1 funding round on record, the most recent an undisclosed round of $4.0M announced in Apr 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cocrystal Pharma Company Profile and Key Stats
Latest funding round on record: Apr 2023.
Cocrystal Pharma Funding Rounds
Cocrystal Pharma Founders and Leadership Team
Contact details for the Cocrystal Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →Cocrystal Pharma Funding Compared to Other Biotechnology Startups
Cocrystal Pharma's latest round of $4.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cocrystal Pharma in Biotechnology and Bothell
Companies Similar to Cocrystal Pharma
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Cocrystal Pharma Funding FAQs
What does Cocrystal Pharma do?
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in Phase 2a studies for the treatment of hepatitis C as part of a cocktail for ultra-short therapy. Cocrystal recently entered into an exclusive worldwide license and collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, the Company’s molecule for the treatment of influenza A, is currently being evaluated in preclinical IND-enabling studies. In addition, the Company has a pipeline of promising early preclinical programs and continues to identify and develop non-nucleoside polymerase inhibitors for norovirus gastroenteritis using the Company’s proprietary structure-based drug design technology platform.
How much funding has Cocrystal Pharma raised?
Cocrystal Pharma has raised $4.0M across 1 round on record. The most recent is an undisclosed round of $4.0M announced in Apr 2023.
When did Cocrystal Pharma last raise funding?
Cocrystal Pharma's most recent funding round on record is an undisclosed round of $4.0M, announced in Apr 2023.
Who founded Cocrystal Pharma?
FundedIQ lists Gary Wilcox (Founder) at Cocrystal Pharma.
Where is Cocrystal Pharma headquartered?
Cocrystal Pharma is based in Bothell, Washington, United States.
How many employees does Cocrystal Pharma have?
Cocrystal Pharma is in the 11-50 employee band.
How does Cocrystal Pharma's funding compare to other Biotechnology startups?
Cocrystal Pharma's latest round of $4.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Cocrystal Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cocrystal Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.